
Imbio is a medical imaging technology company that leverages AI to transform standard medical imaging into personalized medicine. Their product portfolio includes advanced algorithms for lung and cardiothoracic conditions, enabling early disease detection, treatment insights, and progress measurement. With a focus on comprehensive intelligence, proven technology, and global trust, Imbio's solutions are validated by thousands of image series and supported by numerous peer-reviewed publications. The company operates in a scalable and secure manner, offering deployment options that cater to various healthcare environments, making it a key player in the medical imaging market.

Imbio is a medical imaging technology company that leverages AI to transform standard medical imaging into personalized medicine. Their product portfolio includes advanced algorithms for lung and cardiothoracic conditions, enabling early disease detection, treatment insights, and progress measurement. With a focus on comprehensive intelligence, proven technology, and global trust, Imbio's solutions are validated by thousands of image series and supported by numerous peer-reviewed publications. The company operates in a scalable and secure manner, offering deployment options that cater to various healthcare environments, making it a key player in the medical imaging market.
Sector: Medical imaging AI (lung and cardiothoracic)
Founded: 2012
Headquarters: Minneapolis, MN
Regulatory: FDA 510(k) cleared products (e.g., RV/LV Analysis, Lung Density Analysis)
Acquisition: Entered agreement to be acquired by 4DMedical (Dec 2023)
Quantitative analysis and visualization of lung and cardiothoracic medical imaging to improve diagnosis, treatment planning, and measurement of disease progression.
2012
Healthcare / Medical Imaging Software
4080000.00 USD
“Imvenshure LLC identified as a principal investor / portfolio owner; entered binding agreement to be acquired by 4DMedical in December 2023”